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ABSTRACT 
 
Statistical and Economic Implications Associated with Precision of Administering Weight-based 
Medication in Cattle.  (December 2010) 
Isaac Daniel Olvera, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Andy D. Herring 
 
Metaphylactic treatment of incoming feedlot cattle is a common preventative action 
against bovine respiratory disease (BRD).  Cattle are dosed based on estimated or actual lot 
average weights, rather than on an individual basis, to reduce initial processing time.  There has 
been limited research conducted on the effects of accurate weight- based dosing in feedlot cattle.  
The objective of this study was to evaluate the economic effects of precision weight- based 
dosing of cattle as compared to dosing the lot average or lot averages plus 50 lb and minus 50 lb.  
An economic model was created and stochastic simulations performed to evaluate potential 
outcomes of different dosing scenarios.  Economic analyses of the effects of precision weight-
based dosing were conducted using SIMETAR© to determine the stochastic dominance and 
economic effects of different dosing regimens.  
Data were obtained from a commercial feedlot for different lots of cattle where individual 
animal weights were available; for this analysis the minimum lot size was 30 animals, and the 
maximum lot size was 126 animals. Within lots, individual weight deviations were calculated 
from the lot mean, the lot mean was rounded up to the nearest 50 lb increment or down to the 
nearest 50 lb increment to represent mild overestimation and mild underestimation, respectively. 
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Tulathromycin (Draxxin®, Pfizer Animal Health, New York, NY), an antimicrobial commonly 
prescribed for treatment of bovine respiratory disease, was used to illustrate the impacts of 
uniform dosing versus exact dosing per body weight.  Based on the dilution space method used to 
evaluate time of drug effectiveness, it was estimated that Draxxin® administered at the 
recommended dosage to cattle weighing between 500 and 1000 lb should be provided with 191 
hours (7.96 days) of protection from pneumonia-causing bacteria.  Due to the pharmacokinetic 
properties of Draxxin®, an animal that is administered half the recommended dose is only 
protected from pneumonia-causing bacteria for 8 hours, which is 4.2% of the coverage time of the 
proper dose. This limits the effectiveness of the prescribed treatment to fully administer 
therapeutic treatment.  In all cases, the correct weight-based dosing strategy cost less than any 
other dosing technique.  Overall, dosing all cattle at the lot average weight costs $6.04 per animal 
more than dosing at the exact, correct dose.  Dosing all animals at the lot average weight plus 50 
lb costs $6.24 per animal more; dosing all animals at lot average minus 50 lb costs $4.01 per 
animal more.   
The use of individual animal weights to determine per head dosing of Draxxin® is more 
cost effective than using lot averages. This concept would appear to extend to all weight-based 
pharmaceutical products in general, and should be considered a necessary management strategy. 
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CHAPTER I 
INTRODUCTION 
 
 Metaphylactic treatment of incoming cattle in U.S. feedlots is a common method of 
preventative action against bovine respiratory disease (BRD), particularly with high risk cattle.  
With 98% of all feedlots already employing a vaccination protocol, drug efficacy needs to be 
heightened to combat the leading illness, BRD.  Upon initial processing cattle are typically dosed 
based on estimated or actual lot average weights, rather than on an individual basis, to aid in 
reduction of initial processing time. There are a multitude of drugs on the market for the use in 
metaphylactic treatments regimens; one of the newest drugs for the prevention of BRD is 
tulathromycin.  This new, unique, triamlide is thought to be far superior to many of the other 
previous drugs approved for metaphylactic treatment.  The heightened movement and dispersion, 
coupled with the lasting tissue cultures developed aid in making this drug far more efficient, 
when used properly.  There has been limited research done on the effects of accurate weight- 
based dosing in feedlot cattle and associated drug efficacy.     
The dilution space technique has been used to evaluate the amount of water with which a 
substance equilibrates within an animal’s body and used to predict body composition in nutrition 
research.  It appears that this technique is also appropriate to estimate medication dispersion in 
animals’ bodies following injection.   
 
 
This thesis follows the style of the Journal of Animal Science. 
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 Economic analyses that provide cattle producers tools for risk management are needed.  
Risk aversion coefficients in conjunction with stochastic models are effective ways to estimate 
the outcomes based on the probabilities of occurrence and the associated management decision 
based on risk levels. 
 The overall objective of this study was to evaluate the economic effects of precision, 
weight-based dosing in cattle with one specific medication as compared to dosing on the lot 
average weight or lot average weight plus 50 lb (22.7 kg), and lot average weight minus 50 lb to 
account for estimation or rounding errors when using lot average weights.  The urea dilution 
space technique was used as a model here to estimate the dispersion and protection time of 
tulathromycin in the body of live cattle. Based on the resulting estimated protection, an economic 
model was created and stochastic simulation was conducted to evaluate the potential outcomes of 
several different scenarios.  Economic analysis of the effects of precision weight-based dosing 
were conducted through simulation using SIMETAR© to determine the stochastic dominance and 
economic effects of different dosing regimens. 
 
 
 
 
 
 
 
 
 3 
CHAPTER II 
REVIEW OF LITERATURE 
 
Introduction 
Background information will be discussed pertaining to the use of pharmaceuticals, 
Bovine Respiratory Disease and its associated management and economic effects in the U.S. 
cattle feeding industry. The practice of metaphylactic dosing of weight- based medications, the 
use of the antimicrobial, tulathromycin, as a metaphylactic and its associated pharmacokinetic 
properties and the concept of urea dilution space to predict pharmaceutical dispersion in the body 
will be investigated to create a predictive model of efficacy in dosing.  A discussion of risk and 
the use of stochastic models pertaining to economic analysis and the use of the simulation 
program SIMETAR© for economic analyses is also included. 
 
Pharmaceuticals 
The cattle industry is the largest single sector of production agriculture in the United 
States with cash receipts totaling more than $49.2 billion (Lawrence and Ibarburu, 2006), made 
up of approximately 980,000 ranches producing cattle, 85% of which funnel into roughly 2,200 
feedlot operations (Abidoye and Lawrence, 2006).  With so much influence of animal health on 
production and profitability in the cattle industry, it is obvious why livestock pharmaceuticals 
make up a majority of the animal health market. The livestock sector accounts for nearly 70% of 
all animal pharmaceutical sales, but generally remain steady with no growth (Ahmed and 
Kasraian, 2002). Despite the low growth in sales, the animal pharmaceutical industry is 
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consistently undergoing changes and innovations in the areas of drug delivery and the support of 
efficacy, usually aimed at: (1) enhancing consumer convenience and regulation compliance, (2) 
increased efficacy and pharmacokinetic properties of drugs, (3) product differentiation, and (4) 
assurance of target animal and consumer safety (Ahmed and Kasraian, 2002).  In 2007 it was 
estimated that the total added value attributed to pharmaceuticals used throughout the beef 
production cycle was as high as $524 per animal (Lawrence and Ibarburu, 2007).  Obviously in 
challenging economic times any pharmaceutical that increases production efficiency, weight gain 
or fights illnesses is highly desired by producers. 
There are a multitude of products on the market for proper drug dispensing and more 
efficient drug delivery. Most common dispensing apparatuses include single dose syringes, 
multiple dose repeating volume syringes, oral applicators, gun style dispensers, and most 
recently, a novel, scale driven, automated weight based dose delivery syringe system (Animal 
Innovations, Inc., www.animalinnovations.com).  Drug delivery types, much like the dispensing 
products, are highly variable and depend mostly on the convenience and value optimization 
desired, sustainability and stability of drug release, and affected target tissues.  Sustained release 
boluses, oral pastes, pour- on formulas, injectable drugs, controlled internal drug release products 
(CIDRs), implants and ear tags, and feed premixes are all common types of drug delivery 
methods.  With specific regard to injectable drugs, they can be further classified as intramuscular 
(IM), intravenous (IV) or subcutaneous (SC).  Within the feedlot industry, the majority of drugs 
are now given via subcutaneous injection.  Due to the problem of wasted beef product associated 
with IM injections in food animals, the Beef Quality Assurance program made a major industry 
shift towards SC neck injections only in the early 1990’s.  By early 2000, a BQA audit showed 
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that 97.5% of top sirloin butts were free of injection site lesions as compared to 78.7% in 1991 
(Hilton, 2005).  The main animal health products administered to feedlot cattle are parasiticides, 
and vaccines and antimicrobials associated with Bovine Respiratory Disease complex.   
 
Bovine Respiratory Disease and Associated Management 
Bovine Respiratory Disease complex (BRD) is a very extensive disease that encompasses 
both bacterial and viral pathogens; there is much difficulty in differentiating the various entities, 
so the complex as a whole is commonly referred to as Undifferentiated Fever (UF) or simply 
BRD (Booker et al., 2007).  Mannheimia (formerly Pasteurella) haemolytica, Pasteurella 
multocida, Histophilus somni (formerly Haemophilus somnus), and Mycoplasma bovis are the 
primary bacterial pathogens that are threats and whose infections typically manifest themselves 
following viral infection.  The primary viral diseases that are associated with BRD include 
infectious bovine rhinotracheitis (IBR, caused by bovine herpesvirus type 1), bovine viral 
diarrhea (BVD), parainfluenza- 3 (PI3), and bovine respiratory synctial virus (BRSV) (Martin 
and Bohac, 1985). 
Since January of 1992 there have been significant increases in mortality rates within 
feedlots (Babcock et al., 2006).  With the many innovations in preventative medicines and 
medical treatments for cattle and producer education through BQA programs, this fact is 
astonishing.  The most common and costly disease in feedlot cattle, bovine respiratory disease 
(BRD), has shown to be a long plaguing issue within the cattle industry as a whole.  With BRD 
accounting for approximately 75% of feedlot morbidity and almost 50% of mortality (Edwards, 
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1996; Gardner et al., 1999), it is obvious that more in depth research is needed to aid in reduction 
of BRD related cases (Snowder et al., 2006).   
In a study over a six year period spanning from 1994 to 1999 it was shown, using 
collective NAHMS data, that there was  a 38% increase in mortality among feedlot cattle moving 
from 10.3 deaths per 1000 to 14.2 deaths per 1000 cattle; more than half of those deaths (57.1%) 
could be directly attributed to BRD (Loneragan et al., 2001).  Preventative methods to help 
decrease the incidence of BRD upon arrival at feedlots have been studied in depth.  It has been 
shown that preconditioning calves prior to arrival may aid in decreased feedlot morbidity by 6% 
and decrease mortality by 0.7% (Cole, 1985).  A study investigating the added value associated 
with calves prior to shipment from ranch of origin reported that calves weaned and 
preconditioned 45 days prior to shipment had lower incidents of BRD than calves transported 
from the same ranch immediately at weaning or calves assembled at auction markets, even when 
comingled at the preconditioning site (Step et al., 2008).  Furthermore, calves marketed through 
auction barns shipped immediately after weaning had almost double the risk of BRD morbidity 
incident rates than calves that were weaned prior to shipping (Roeber et al., 2001). 
 
Economic Effects of BRD on Feedlots 
The economic effects associated with incidents of BRD are staggering.  The economic 
impact of BRD alone has been reported to cost the cattle industry $800- $900 million annually 
(Griffin, 1997; Chairase and Greene, 2001).  Snowder et al. (2006) estimated that the individual 
treatment cost per animal was $13.90; therefore the total economic loss associated with BRD in 
1,000 feeder calves was approximately $13,895 not including the cost of feed prior to mortality, 
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labor costs, or associated handling. Research supports that for every 10% increase in feedlot 
morbidity linked with BRD, medicine cost increase $2 per head for all cattle that are finished 
(Edwards, 1996).  With 11.6 million cattle on feed in 2009 a simple $2 increase could cost the 
industry more than just increased production costs (NASS, 2010).  In markets that compete on 
costs any additional inputs needed have some corresponding price increase at the retail level.  The 
USDA has stated the own price elasticity of beef as -.621, meaning that for every observed 10% 
increase in price there is an associated 6.21% decrease in quantity demanded (USDA, 2008).  
Price fluctuations associated with cost management in the production sector have a larger impact 
on beef sales and marketability than just profitability of the individual producer, these cost carry 
through to the consumer level and directly affect the industry at the sales level. 
There has been extensive work done on the factors affecting profitability in cattle 
associated with BRD.  Gardner et al. (1999) specifically noted that the disease resulted in 
consistently lower average daily gains, lighter hot carcass weights, and lower marbling scores; 
furthermore, the presence of lung lesions associated with respiratory disease could be highly 
correlated to the reduction in performance.  Steers diagnosed with respiratory disease at slaughter, 
based on pulmonary lung lesions and active bronchial lymph nodes, returned $73.78 less than 
animals without lesions.   Approximately 21% of the deductions were attributed to the cost of 
treatments and medications, the remaining 79% were attributed to the reduction in hot carcass 
weight (8.4% less) as well as reduced quality grades (24.7% more US Standard carcasses in 
group with lesions) (Gardner et al., 1998).  It is not uncommon for the cost of morbidity to 
outweigh the cost of mortality, a death early in the production cycle can save on feed, 
medications and associated handling costs.  If the death occurs early enough in the production 
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cycle the only loss attributed to the animal is the purchase price.  The additional costs of lower 
average daily gains, lower carcass values and less desirable products can inflate the cost of 
morbidity to $92.26 for animals that were ill as compared to those that were not (McNeill et al., 
1996).  
 
Feedlot Metaphylactic Dosing 
In general, feedlots are one of the largest adopters of pharmaceutical technologies. 
Lawrence and Ibarburu (2006) reported that at initial processing, approximately 98% of all 
feedlots vaccinated incoming cattle against respiratory disease. One of the more widely practiced 
time management strategies used in feedlots is metaphylactic treatments.  Metaphylaxis, also 
referred to as mass medication, is a preemptive strike against cattle that may be considered high 
risk for contracting or spreading illness; dosing all incoming cattle at initial processing with an 
approved antimicrobial.  When administering metaphylactic treatment, feedlots will often process 
hundreds of incoming cattle at a time so efficient time management is a necessity.  Many factors 
influence the decision to treat incoming cattle metaphylactically, including shipping distance, 
arrival weight, appearance, BRD incidence from cattle within the same region, source, season, 
age, etc.  With these factors considered, it was shown that larger feedlots, defined as 8,000 head 
or larger, were 54.4% more likely to employ the use of metaphylactic treatments aimed solely at 
combating BRD alone within their feedlot compared to smaller operations of 1,000 to 7,999 
animals (USDA, 2000).   
Upon arrival, cattle may be sectioned into one of two categories, high risk and low risk 
type cattle (Edwards, 1996).  Cattle deemed high risk generally include: calves recently weaned, 
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cattle that have been trailered long distances, groups of cattle that were purchased and grouped at 
auctions, cattle that are considered high stress when they arrive, and cattle that have had low 
exposure to unfamiliar other cattle.  Low-risk cattle include: single source cattle, pre- weaned 
calves, yearling cattle and cattle coming from preconditioning/ stocker operations (Booker et al., 
2007; Step et al., 2007; Sanderson et al., 2008).   
 
Tulathromycin as a Metaphylactic  
 Much research has been completed on the efficacy of metaphylactic treatments for cattle 
entering feedlots.  As stated earlier, 80.9% of large feedlots (54.4% more than smaller feedlots) 
employ the use of metaphylactic treatments to help prevent BRD outbreaks (USDA, 2000).  For 
the purpose of this research we focused on the use of tulathromycin (Draxxin Injectable Solution, 
Pfizer Animal Health) as the metaphylactic antimicrobial of choice.   
 Tulathromycin was developed for the prevention and treatment of respiratory disease in 
cattle and pigs (Booker, 2007).  Due to the pharmacokinetic properties of tulathromycin, 
compared to other similar macrolides (erythromycin, tylosin, spiramycin and tilmicosin), the long 
lasting effects and rapid dispersion and movement are thought to make it superior to most other 
metaphylactic antibiotics.  Despite the fact that Tulathromycin is two to three time more 
expensive than other macrolides, it may be more cost effective for the prevention of BRD.  In an 
economic study of metaphyactics, tulathromycin was shown to have an advantage of $16.43 and 
$3.67 per animal over oxytetracycline and tilmicosin when administered metaphylactically; this 
was due to the lower treatment and retreatment rates, lower mortality incidents, improved average 
daily gain and higher quality grades, despite higher dosing costs and lower yield grades observed 
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on both antibiotics, lower feed efficiency compared to tilmicosin (Booker et al., 2007).  Booker et 
al. (2007) concluded that through the use of tulathromycin fewer animals are at risk for incident 
of BRD. By reducing morbidity, the associated treatments are reduced, thus aiding in (1) reduced 
amount of antimicrobials administered in the beef production industry, (2) increased profit 
potential for producers, and (3) improved welfare of cattle with reduced handling, stress and 
isolation.  
 
Pharmacokinetic Properties of Tulathromycin 
 Tulathromycin was the first product classified as a tribasic macrocyclic antibiotic, now 
referred to as triamilides (Nowakowski et al., 2004).  Triamilides are semisynthetic derivatives of 
the natural product, erythromycin (commonly used in humans for respiratory ailments), and are 
characterized by the presence of three polar amine groups (tribasic) that differentiate them 
structurally from other macrolides (Letavic et al., 2002).  Tulathromycin is formulated in an 
equilibrated mixture of two macrocycles for subcutaneous or intravenous injection as a single 
dose to provide a full course of treatment against respiratory bacterial pathogens in cattle and 
swine.  It is thought that unique features of the triamlide class enhance penetration of gram-
negative bacterial pathogens, resulting in increased drug potency and effectiveness (Evans, 2005). 
Generally, antibiotics are classified as bacteriostatic, bactericidal or a both; but typically 
the macrolides are considered bacteriostatic.  This means they inhibit bacterial growth by 
preventing essential protein biosynthesis through selective binding to bacterial ribosomes and 
stimulate dissociation of peptidyl -tRNA from the ribosome during the translocation process 
(Vannuffel and Cocito, 1996), meaning they inhibit cell division and lead to cell death. 
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Tulathromycin is unique in that it exhibits both bacteriostatic and bactericidal features.  The 
minimum inhibitory concentration (MIC) for 70% (the minimum concentration of a drug 
necessary to inhibit 70 percent growth, associated with being bacteriostatic) was found to be the 
same as the minimum bactericidal concentration (MBC) for M. haemolytica and P. multocida 
(Evans, 2005).   So, along with preventing cell division, tulathromycin’s tribasic structure aids in 
penetrating the gram negative pathogens, the most common cause of BRD, aiding in attacking 
these pathogens. 
Aiding in the movement of tulathromycin and its associated efficacy is the ability of the 
drug to use phagocytic cells to help store and move the drug.  Data suggest that heightened 
concentrations in infected lungs can be attributed to tulathromycin moving with immune cells to 
affected areas and being secreted slowly into the extracellular area where it can be used to attack 
pathogens.  As well, evidence supports that the leukotoxins produced by the gram- negative 
organisms, such as M. haemolytica, induce lysis of the phagocytic cells carrying the drug (Evans, 
2005).   
  The ability of the tissue concentration of tulathromycin to remain high for an extended 
period of time is presumed to be the underlying reason behind the high efficacy rates observed; 
after tulathromycin is administered, the bioavailability is approximately 91% (Skogerboe et al., 
2005).  Tulathromycin is metabolized slowly, and a majority of the remaining drug is excreted in 
feces and urine.  Because tulathromycin is absorbed rapidly into the tissue, lung concentration is a 
better predictor of the pharmacodynamic properties than the use of plasma concentrations for 
efficacy models based on concentrations (Evans, 2005).  
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Urea Dilution Space 
 The urea dilution technique was developed in an effort to adequately and efficiently 
predict the body composition of cattle in vivo through estimating empty body water concentration 
as a calculation of a percent of total composition.  Because urea is inexpensive, and it is 
somewhat easy to analyze the plasma urea nitrogen content, the urea dilution technique is more 
readily applied in both research and industry where measurement of body composition during 
growth may be necessary (Rule et al., 1986).  It was the only method emerging that was time 
efficient and accurate.  Before then, methods included backfat measurement tools, ultrasonic 
probes, visual appraisal or use of titrated water or deuterium oxide (used in humans) as dilution 
constants (Bartel et al., 1983).  The other dilution constants often required several hours to 
adequately determine body composition, as well as including a factor known as turnover rate. The 
turnover rate estimated the body water dilution much the way the urea dilution technique does but 
required more time, especially during peak lactation and increased during gestation, and required 
the use of specialized equipment to calculate.   
Unlike the other dilution methods, the urea dilution technique was reported to work as 
quickly as 12 minutes and accurately report the body water percent (Bartel et al., 1983).  
Soberman et al. (1949) stated that substances to be used in body composition estimates as 
physiological tracers should “show an even and rapid distribution throughout the body water, 
should be nontoxic, not foreign to the body and not cause any physiological disturbances." As 
well, tracer substances should be “accurately and easily measured in either whole blood or plasma 
and they should not be selectively stored, secreted or metabolized.”  The urea dilution technique 
was validated by Bartle et al. (1987) for the estimation of body composition.  They concluded 
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that the technique met all the requirements of a proper tracer in cattle.  Urea space was defined by 
Kock and Preston (1979) as the volume of water with which urea equilibrates. They made the 
assumption that urea space is correlated with empty body water, therefore urea space 
measurements could be used as adequate predictors for estimating body composition in cattle. 
   
Risk 
Risk is defined as a part of the business decision out of the manager’s control 
(Richardson, 2010).  Hardaker et al. (2004) identified six specific areas of risk observed in 
agricultural production as a whole: (1) production risk (2) price risk (3) institutional risk (4) 
human/ personal risk (5) business risk and (6) financial risk; the following is a discussion of the 
areas regarding risk in agriculture. Production risk comes from the unpredictable nature of 
agriculture as a whole: weather, illness, livestock growth and performance, morbidity/ mortality 
rates in a given year and pasture quality or availability are all areas of concern in production risk. 
Additionally, production risk extends to the highly variable prices of farm inputs and outputs that 
usually aren’t certain at a given point in the future. Price risk associated with production usually 
includes risks associated with the high amounts of commodities needed in livestock production. 
Market volatility can often cause sudden price changes that a producer may not have accounted 
for, as well as, the variability in the supply and demand changes of product. Institutional risk is a 
risk that governing bodies introduce through the implementation of various rules and policies. 
Institutional risk can be further broken down into: political risk (risk of adverse policy changes), 
sovereign risk (risk that foreign governments will fail to uphold predetermined agreements and 
commitments), and relationship risk (risk from issues between partners or other organizations).  
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Fourth, there is the human/personal risk aspect.  This is a risk that develops within the 
management of the firm. Crises such as death or serious illness of integral team members may 
interfere with of the processes of normal daily operations.   
Business risk is the combination of production, market, institutional, and personal risk.  
Business risk impacts the firms’ business performance in terms of the net cash flow generated or 
net farm income earned.  Finally, financial risk results from financing options of the firm. Bank 
and loan issues or investor shortcomings are all common issues in financial risk. 
It has been stated “the purpose of simulation in risk analysis is to estimate distributions of 
economic returns… so the decision maker can make better management decisions” (Richardson, 
2010).  There are two types of simulation models to help analyze economics returns, 
deterministic models and stochastic models. Deterministic models do not take risk into account 
and only calculate outputs based on input variables. They are adequate for investigating the 
outcomes based on managerial changes, but do not assume a risk variable, and are therefore static 
compared to the business environment. 
 
Stochastic Models 
Stochastic models incorporate some sort of uncertainty or, an assigned risk variable.  
Incorporating risk into a model allows managers to create alternative scenarios and analyze the 
probabilistic outcomes of the model.  Once modeled, a manager must select the most appropriate 
economic option with the goals of the individual operation in mind.  Without assessing risk 
within a model the simulations for alternative scenarios will not be adequate to base decisions 
upon. If there was no risk in a business environment, the optimal strategy would simply be that 
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which has the greatest economic return. With a risk variable included, the decision becomes 
much more complex. Economic returns associated with the risk of losses may force the selection 
of a less profitable but more stable alternative based on the assumption of less risk resulting, in 
the long run, in a more stable economic environment (Hardaker et al., 2004).  
The main goal of simulating risky alternatives is to allow for accurate decisions to be 
made on economic issues that may be too large, complex, costly or lengthy to actually perform.  
Most models are quite easily adapted to changes within the firm’s business environment and can 
be used to train new management in procedures without exposing the business to actual risk. 
Although models can be an extremely effective tool for analyzing a given scenario, people will 
largely discredit the use of simulations based solely on human error, or they will put full faith in 
the model because “that’s just what they’re supposed to do” (Richardson, 2010). Models are only 
as good as they are built, and confined by the data used to create them. 
 
Simulation and Econometrics to Analyze Risk 
Simulation and Econometrics to Analyze Risk (SIMETAR©) is a front loaded Microsoft 
Excel based program developed by Richardson, Schumann and Feldman in the Department of 
Agricultural Economics, Texas A&M University (Gill et al., 2003).  It utilizes Visual Basic 
programming to work directly in Microsoft Excel.  SIMETAR©  was specifically written for 
analyzing data, simulating risky alternatives and presenting findings.  Of the more than 230 
functions in SIMETAR©, they can be categorized into seven groups: 1) simulating random 
variables 2) parameter estimation and statistical analysis 3) graphical analysis 4) ranking risky 
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alternatives 5) data manipulation and analysis 6) multiple regression and 7) probabilistic 
forecasting (Richardson, 2010).   
Monte Carlo simulations use random sampling of probability distribution functions as 
model inputs, the simulation process produces possible outcomes based on the stochastic inputs.  
The results show the probabilities of the occurrence of each outcome given the actual data set.  
SIMETAR©  gives the user the option to use one of two Monte Carlo simulation methods, Latin 
Hypercube and Monte Carlo distribution.  Richardson (2010) gives an adequate explanation of 
the two methods, cited in the following discussion. The Latin hypercube procedure is the 
preferred method of sampling probability distributions.  Latin hypercube breaks the distributions 
into N intervals and randomly selects at least one value from each interval.  The number of 
intervals, N, is the number of iterations used in the model.  By sampling from N intervals, the 
Latin hypercube method insures that all areas of the probability distribution are weighted within 
the simulation model, making fewer iterations necessary to produce an accurate replication of the 
data set.  The Monte Carlo procedure randomly selects values based on the probability 
distribution.  As a result, the Monte Carlo method samples a greater percentage of random values 
about the mean, therefore, under samples the areas in the tails.   A larger number of iterations 
must be used to more accurately account for all of the distribution area and minimize the effects 
of under sampling in the tails of the probability distribution. 
 
Summary 
 The economic effects associated with the use of precision dosing in metaphylactic 
treatments need much investigation. With more than 11 million cattle on feed, any amount of 
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monetary changes in the industry can cause a drastic change in economic returns within the 
industry as a whole.  Much work is needed to investigate what the social and economic effects 
directly associated with precision dosing of weight-based medications; therefore, the objective of 
this study was to evaluate the economic effects of precision weight-based dosing in cattle as 
compared to dosing on the lot average. The general concepts associated with the urea dilution 
space equation used to measure in vivo body composition were utilized to estimate antimicrobial 
concentrations in animal tissues. An economic model and stochastic simulation was constructed 
to evaluate the outcomes of exact weight dosing, lot average weight, lot average weight plus 50 lb 
and lot average weight minus 50 lb.  Economic and statistical analyses of the effects of precision 
weight based dosing were conducted to determine the outcome effects of different dosing 
regimens. 
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CHAPTER III 
STATISTICAL AND ECONOMIC IMPLICATIONS ASSOCIATED WITH PRECISION OF 
ADMINISTERING WEIGHT-BASED MEDICATION IN CATTLE 
 
Introduction 
The use of metaphylactics to treat incoming cattle in U.S. feedlots is a common method of 
preventative action against bovine respiratory disease (BRD).  Upon initial processing cattle are 
typically dosed based on estimated or actual lot average weights, rather than on an individual 
basis, to aid in reducing the initial processing time necessary. There are a multitude of drugs on 
the market approved for the use as metaphylactics; one of the newer drugs recently approved for 
the prevention of BRD is tulathromycin.  This new, unique, triamlide is thought to be far superior 
to many of the other drugs previous used in metaphylactic treatments.  There has been limited 
research done on the effects of accurate weight- based dosing in feedlot cattle and associated drug 
efficacy.   
The dilution space technique was has been used to evaluate the amount of water with 
which a substance equilibrates within an animal’s body.  This technique was used here to 
estimate the dispersion and coverage of tulathromycin. Based on the estimated coverage, an 
economic model and stochastic simulation were created to evaluate the potential outcomes of the 
different scenarios.  Economic analysis of the effects of precision weight based dosing were 
conducted using SIMETAR© to determine the stochastic dominance and economic effects of 
different dosing regimens. Risk aversion coefficients in conjunction with stochastic models are 
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effective ways to estimate the outcomes based on the probabilities of occurrence and the 
associated management decision based on risk levels. 
 
Materials and Methods 
Data were obtained from a commercial feedlot for different lots of cattle that were 
delivered from 2007 to 2009 where the feedlot had individual animal weights upon arrival (all 
weights herein are denoted in common U.S. industry standard notations i.e. 50 lb, 100 lb and 
1000 lb increments). This is not the case for most commercial U.S. feedlots. For this analysis, the 
minimum lot size considered was 30 animals, and the maximum lot size evaluated was 126 
animals. Summary statistics of each lot are shown in Table 3.1. Skewness (the relative inequality 
of weighting in the tails of the distribution) and kurtosis (a measure of the pattern of dispersion) 
were calculated.  The percent of animals falling within ten percent of the lot mean also were 
calculated to examine the relative average lot dispersion. Within lots, individual weight 
deviations were calculated from the lot mean for each animal. Additionally, because mean lot 
weights are often estimated at arrival rather than calculated overtly, the lot mean weight was 
rounded to the nearest 50 lb increment to represent mild overestimation and mild 
underestimation, respectively. For example, if the lot mean weight was 642 lb, then the 
overestimated mean was projected at 650 lb and the underestimated mean was projected at 600 
lb, etc.  
Tulathromycin (Draxxin®, Pfizer Animal Health, New York, NY), an antimicrobial 
commonly prescribed for treatment of respiratory disease, and also often applied en masse for 
control therapy strategies, was used to illustrate the impacts of uniform dosing versus exact  
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Table 3.1 Summary statistics of lot weight, variation, and distribution in regard to normal distribution assumptions and weight-
based medication efficacy. 
 Lot 
 A B C D E F G H I J 
Mean, lb 1006.97 639.395 661.658 631.285 329.3 973.636 584.602 470.185 1128.90 475.710 
St.Dev., lb 104.796 68.5685 75.8332 40.7709 57.6237 112.848 77.0361 103.564 112.674 87.5241 
95 % LCI 979.295 621.995 646.333 615.145 304.476 934.155 563.19 441.831 1093.55 451.566 
95 % UCI 1034.65 656.794 676.984 647.425 354.124 1013.11 606.015 498.540 1164.26 499.853 
CV 10.4070 10.7239 11.4610 6.45839 17.4988 11.5903 13.1775 22.0263 9.98088 18.3986 
Min 804 490 472 540 245 820 360 310 920 300 
Median 1000 640 670 630 320 936.5 578.5 460 1118 460 
Max 1350 775 825 740 500 1315 800 790 1425 740 
Skewness 0.69420 -0.0706 -0.19031 0.51703 1.11306 1.03767 0.12527 1.11230 0.55927 0.73142 
Kurtosis 0.93274 -0.5829 -0.32885 1.29276 1.78500 0.87316 0.99925 1.35153 -0.10762 0.84060 
10% of mean 0.66338 0.6484 0.61752 0.87803 0.43212 0.59083 0.55259 0.34993 0.68354 0.41355 
Count 75 81 126 35 30 44 68 70 54 69 
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dosing per body weight on product usage and cost overruns in arriving feedlot cattle.  Other drugs 
were examined for use as metaphylactics in this study, but tulathromycin offered the most 
complete label information.  It has become widely used in the industry as a metaphylactic and is 
the most cost influential medication based on price per mL of the labeled dose. Table 3.2 shows 
the break down of the various BRD treatment medications investigated.  The labeled dosage for 
tulathromycin is 1.1 ml per 100 lb BW, and per unit product cost was set at $4.43 per ml. Product 
prices reflect reported retail prices from January 2009. 
 
 
Table 3.2. Similar medications investigated for use as metaphylactics in feedlots.1 
 
Chemical            
Name Product 
 
Company          Price 
Price/ 
mL Dose Rate MIC90 (µg/mL) 
       ceftiofur 
crystalline free 
acid 
Excede Pfizer $163.95/100mL $1.64 1.5mL/100lb 
M. haemolytica 
.025 
P. multocida 0.004 
tulathromycin Draxxin Pfizer $2213.60/500mL $4.43 1.1mL/100lb 
M. haemolytica 2 
P. multocida 1 
enrofloxacin Baytril Bayer $194.95/250mL $0.78 3.4 - 5.7 mL/100 lb 
M. haemolytica .06 
P. multocida .03 
oxytetracycline Tetradure Merial $125.00/500mL $0.25 13.6mg/lb (300mg/mL) 
tilmicosin 
phoshate Micotil Elanco 339.95/250mL $1.36 1.5mL/100lb 
M. haemolytica 
3.12 
1 Prices relative to January 2009. 
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 Three specific methods were employed to evaluate the effectiveness of administering the 
weight-based product: (1) estimation of product dispersion through the animal’s body in order to 
provide protection against pneumonia-causing bacteria using the dilution space evaluation, (2) 
estimation of the level of protection against illness provided to animals that receive varying 
percentages of recommended dose of weight-based , and (3) estimation of changes in expected 
illness and correlated costs associated with dosing animals at varying levels of their 
recommended weight-based dose.  These are described individually below. 
(1) Estimation of product dispersion in animal’s body from injection 
Below are the drug properties, assumptions and description of the methodology used to 
estimate the time associated with the effectiveness of the weight-based medication Draxxin®.   
  Concentration: 100 mg/mL 
  Dosing: 1.14 mL/cwt (1 mL/40 kg) 
Lung Capacity of Draxxin®  (from label description and Pfizer web site): 
Tmax (hours):  24 
Cmax (μg/mL):  4.1 
T1/2 (hours): 184 
MIC 90:  2 (μg/mL) 
The procedure used to estimate diffusion of the medication through the body in order to 
predict the concentration in the tissue is referred to as dilution space evaluation.  Kock and 
Preston (1979) used the urea dilution technique to estimate an animal’s body composition in vivo.  
In that study, urea was used as the chemical marker to determine how it diffused in the water of 
the animal’s body.  Urea space was defined by Kock and Preston (1979) as “the volume of water 
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with which the urea equilibrates.” The formula they used to determine the dilution space is 
provided below.  
 
Volume infused (mg) ÷ [Known Peak (mg/100mL) * LW(kg)] = Dilution Space (DS) 
 
This equation was used to estimate the area, as a percentage of body weight, that a drug is 
allowed to diffuse into. The peak concentration reported for Draxxin® was 4.1 μg/mL; therefore, 
concentration of the medication was assumed to be 0.41 mg/100 mL of product. 
 Volume infused and live weights were both calculated on an individual animal basis. 
The following weight classes of cattle were evaluated to derive a dilution space constant that 
could be used to predict medication concentration relative to recommended weight-based dosage:  
   
   1000 lb = 1140 mg/(.41 mg/100 mL*453.59 kg) = 6.1300 
   900 lb = 1020 mg/(.41 mg/100 mL*409.09 kg) = 6.0812 
   800 lb = 912 mg/(.41 mg/100 mL*363.64 kg) = 6.1170 
  700 lb= 798 mg/(.41 ml/100 mL*318.18 kg) =6.1171 
  600 lb= 684 mg/(.41 ml/100 mL*272.73 kg) =6.1170 
  500 lb= 570 mg/(.41 ml/100 mL*227.27 kg) =6.1182 
 
As a result, the dilution space constant of 6.1 can be used across all weight classes of cattle for 
tulathromycin.  The dilution space equation was modified to calculate the maximum tissue 
concentration. The equation below incorporated the dilution space value to estimate the 
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maximum concentration of the medication in the tissue when varying percentages of weight-
based medication were administered to a 1,000 lb animal. 
 
Volume infused (mg) ÷ [DS * Live Weight (kg)] = Max Concentration (N0) 
  
 Correct Dose = 1140 mg/ (6.1 *453.59 kg) = .41 
  10% reduction = 1026 mg/ (6.1*453.59) = .3708 
  20% reduction = 912 mg/ (6.1*453.59) = .3296 
30% reduction = 798 mg/ (6.1*453.59) = .2884 
40% reduction = 684 mg/ (6.1*453.59) = .2472 
50% reduction (half-dose) = 570 mg/(6.1*453.59) = .2060 
 
(2) Protection of animals receiving different levels of the weight-based recommended dose 
The equation: T1/2 = ln2 ÷ λ describes the half-life of a medication with a logarithmic 
decline in concentration; the half life of tulathromycin is reported to be 184 hours.  As a result:  
 184 = .693 ÷ λ  λ = Decay Constant = .003766 
 
And, the quantity remaining in the tissue at time t (Nt) can be estimated as: 
Nt = N0-λt where 
 N0 = initial quantity to be decayed 
  λ = decay constant 
 t = time in hours 
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 As a result, the effective number of hours that animals would be protected from the 
correct weight-based dose of tulathromycin was calculated where the tissue MIC 90 value was 
maintained; the number of hours of protection were also calculated for animals receiving 90%, 
80%, 70%, 60% and 50% of the recommended weight-based dose.  The distribution is displayed 
in Figure 3.1. 
 
 
 
 
Figure 3.1.  The decrease in effectiveness of the medication Draxxin® through 368 hours 
following administration of a correct, weight-based dose and 90%, 80%, 70%, 60% and 50% of 
the correct, weight-based dose.  The dark blue horizontal line is the concentration of Draxxin® 
that provides tissue minimum inhibitatory concention of 90% (MIC 90) for M. haemolytica 
(causative bacteria of pnuemonia). 
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(3) Estimation of economic costs due to not using recommended weight-based dose 
The total economic loss associated with BRD in 1,000 feeder calves was estimated to be 
$13,895, not including feed prior to death, labor or handling costs (Snowder et al., 2006). With a 
stated morbidity rate of 14.4%, or 144 calves in the lot, the per incidence cost of sickness 
($13,895/ 144) came to $96.49 per sick animal; as a result $96.49 was the value assigned to 
represent the cost of a sick animal.  Cattle were assumed to be in processing chutes, presumably 
with a weigh scale in or directly attached to the head gate; the additional cost to collect the weight 
and dose the animal correctly would be minimal if any. Therefore, the costs to collect weight data 
were not associated with the total economic input cost.  
Based on the reported pharmacological values and morbidity rates for Draxxin®, the 
variation from individual animal weights from a commercial feedlot, and the described economic 
assumptions, a simulation model was developed that compared the costs associated with (i) exact, 
weight-based dosing, (ii) dosing where each animal received the dose associated with the average 
weight of the lot, (iii) dosing based on the lot average weight plus 50 lb, and (iv) dosing based on 
the lot average weight minus 50 lb. 
 Economic analyses utilized the actual weight distributions for the individual lots as well 
as an overall (all lots combined) distribution along with the previously described assumptions for 
costs and morbidity to randomly simulate 500 different lots of cattle with the same average and 
standard deviation of each individual lot.  The data analysis package Simulation and  
Econometrics to Analyze Risk (SIMETAR©) was used to create an economic simulation model 
 to evaluate the cost of the different dosing regimens. Each individual animal’s specific weight 
within the lots was created to be a stochastic variable, being empirically distributed between the 
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lot maximum and minimum, around the actual lot means and standard deviations.    The animals 
were assigned a uniformly distributed number, designated the sickness variable, to be the variable 
that would denote sickness at the end of the model.  An incoming sickness variable was assigned 
to designate cattle that were sick upon arrival to the feedlot, with the assumption that cattle that 
were not sick when they arrived and were treated initially would not become sick.  The coverage 
rate and adjusted coverage rate variables account for the amount of time the animal was covered 
from the given dose of Tulathromycin. Animals in the “Exact Dosing” lots were always assigned 
a perfect coverage rate of 1 or full coverage for their respective weight.  Animals that were 
overdosed were adjusted to a maximum of 1. It has not been shown that there is an additive effect 
of overdosing in coverage time. The morbidity index is the adjusted coverage rate multiplied by 
the sickness variable to account for the effects of drug on the animals.  The morbidity rate is the 
determinant of which animals remain sick after treatment within the lots.  For the purpose of this 
analysis, the morbidity rate was set at 0.25, in other words, if the morbidity index was below 0.25 
then the animal was determined to be sick.  The threshold value of 0.25 was based on estimated 
morbidity rates found by Pfizer in field studies of tulathromycin. It was considered to be an 
adequate assumption of morbidity based on other research estimates as well.  As discussed 
earlier, the cost of sickness was assigned a value of $96.49 per incident.  Each animal designated 
as sick was assessed the cost of sickness, and all animals were assigned treatment costs based on 
the amount of Tulathromycin administered.  Each lot was simulated 500 times using a Latin 
Hypercube simulation to observe the distributions and probabilities associated with each cost 
incidents.   Based on the simulation output, the 500 iterations run in SIMETAR© were graphed 
into cumulative distribution functions (CDF graphs) to show graphically the cumulative 
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probability of a specific price event occurring. A Stochastic Efficiency with Respect to a Function 
chart (SERF chart) was used rank the dosing options.  A relative risk neutral assumption was 
used when creating the SERF charts. Table 3.3 gives an example of the SIMETAR© simulation 
created to analyze the cost of sickness.  
 
Results and Discussion 
Based on the dilution space approach to evaluate time of drug effectiveness, it was 
estimated that Draxxin® administered at the recommended dosage to cattle weighing between 500 
lb and 1000 lb should be provided with 191 hours (7.96 days) of protection from pneumonia-
causing bacteria (where the lung tissue concentration should be above the MIC 90 level of 
protection).  Pfizer recommends that animals injected with Draxxin® should not be given another 
injection for 7 days, this recommendation supports the basis for the coverage time being 191 
hours.  Table 3.4 shows the estimated time of coverage that animals receive when dosed at 
various percentages (100% to 50% reduced in 10% increments) of the recommended weight-
based dose.  Due to the pharmacokinetic properties of Draxxin®, an animal that is administered a 
half-dose is only expected to be protected from pneumonia-causing bacteria for 8 hours, which is 
4.2% of the coverage time of the proper dose.  Therefore, it follows that there is a non- linear 
relationship between coverage time and dosing, and when using a dosing regimen accuracy can 
be a key factor in efficacy related problems. 
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Table 3.3. Example of model input parameters1 used to evaluate economic costs associated with weight-based medications.  
 
1This is the model of a lot with an average of 550 lbs. 
Weight - empirical distribution based on actual data and weight distributions from commercial feedlot 
Sickness variable - a uniformly distributed number used to adjust coverage rates and help add more variability or less 
consistency between like weights. 
Sick/not - 1 = sick, 0 = not sick. A 50% distribution based on Draxxin® studies showing approximately a 50% morbidity rate 
of a saline substitute.  
Coverage rate/Adjusted coverage rate - the coverage of the animals actual weight as a percent of the weight used in the 
evaluation (lot average, lot average +50 lb, lot average -50 lb) and, if over 1 it is adjusted to reflect only 1. It is unknown if 
additional dosing aids in prevention. 
Morbidity index - the morbidity index (between 0 and 1) is the adjusted coverage rate multiplied by the sickness variable to 
help account for the change in the percent coverage of the drug.  
Morbidity rate - this is a variable that determines what percentage of the morbidity index will be sick. It is currently set a 25%, 
or if the morbidity index is below .25 then the animal is determined to be sick in the simulation as seen in the first model. 
Morbidity cost - this is the cost associated with a sick animal set as a constant of $96.49. 
Dose cost - the amount of drug dosed by weight to the animal based on exact, average, average +50 or average -50. In this 
case, a lot average of 550 lbs 
Total cost - morbidity plus the dose cost.
Average(-50)  550 lbs         
Weight Sickness Var Sick/Not CovRate AdjCov Morb Index Morb Rate Morb Cost Dose Cost Total Cost 
600 0.255950 1 0.9192 0.919 0.2378 1 $ 96.49 $ 27.78 $124.27 
550 0.250885 0 1.0027 1 0 0 $         - $ 27.78 $ 27.78 
500 0.260620 1 1.103 1 0.2607 0 $         - $ 27.78 $ 27.78 
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Based on research by Evans (2005), pertaining specifically to the pharmacokinetic 
properties of tulathromycin, models using plasma concentration based time dependency 
(concentration duration above MIC) fail to adequately predict the observed efficacy due to the 
rapid dispersion rates of tulathromycin into tissue.   The time exposure to the pathogens in lung 
concentrations are a more adequate predictor of efficacy, but still does not capture the full 
advantages of the movement and targeting associated with the triamilide class of antibiotics. 
This model is based on the stated maximum lung concentrations related to the MIC 90 for M. 
haemolytica, and is therefore a conservative estimate of the actual full effective rate of 
tulathromycin. In a field trial the expected sickness should be less than that stated in the model 
overall, and much less for the exact dosing.  
 
 
Table 3.4.  Amounts of time cattle should be protected from pneumonia-causing bacteria (MIC 
90)1 when administered Draxxin® at recommended, weight-based dosage and varying deviations 
(90%, 80%, 70%, 60% and 50%) of dose.                                                                                             
% Max 
concentration 
reduction 
Time above 
MIC90 (hrs) 
% Coverage time 
vs. recommended 
% Less coverage 
time vs. 
recommended 
Hours of 
reduced 
protection vs. 
correct dose 
0 (100% dose) 191 100 0 0 
10 (90% dose) 164 85.86 14.12 27 
20 (80% dose) 133 69.63 30.37 58 
30 (70% dose) 98 51.31 48.69 93 
40 (60% dose) 57 29.84 70.16 134 
50 (half dose) 8 4.19 95.81 183 
 
1MIC 90 = Minimum inhibitory concentration to prevent 90% of bacterial proliferation. 
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Outputs from the economic simulations are presented in Figures 3.2 and 3.3.  This 
analysis indicates that the correct, weight-based dose cost less than any other dosing 
technique, showing the real economic incentive for more precise management.  The SERF 
value chart is a stochastic efficiency with respect to a function, or in this case, how much 
money would it take to match the next best alternative and make someone indifferent to the 
additional cost.  In this output, a reasonably risk neutral manager would always choose to dose 
at the exact weights, followed by the lot average weight minus 50 lb. The final two would be 
 
 
 
 
Figure 3.2. Cumulative Distribution Function (CDF) approximations from simulation study that 
show total costs associated with weight-based dosing scenarios using Draxxin® for exact weights, 
lot average weight, lot average weight plus 50 lb, and lot average weight minus 50 lb based on a 
group of 652 animals. 
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determined by the preferences of the individual manager since the lines intersect.   
The risk neutral manager in this case would rather dose at 50 lb below the lot average weight than 
50 lb over the lot average weight.  While surprising at first, this finding is logical when 
examining observed costs.  A manager in an attempt to reduce up front processing costs would 
under dose, seeing the initial observed costs of medications decrease.  The loss of value in 
sickness and quality may not be directly observable by the manager, therefore, is an overlooked 
loss value associated with the under dosing.   
 
 
 
Figure 3.3. Stochastic Efficiency with Respect to a Function (SERF) values associated with 
various weight-based dosing scenarios (exact weight, lot average weight, lot average weight plus 
50 lb, and lot average weight minus 50 lb) using an Absolute Risk Aversion Coefficient (ARAC) 
between 0 and 1 implying complete risk neutrality in decision management for a group of 652 
animals. 
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Table 3.5 shows the costs associated with dosing all animals at the lot average weight, 
dosing all animals at the lot average weight plus 50 lb, and the lot average weight minus 50 lb, as 
well as all animals together on a per animal basis.  These comparisons are made and interpreted 
most easily at the 50th percentile, and the results described below are differences at the 50th 
percentile.  Overall, dosing all cattle at the lot average weight costs $6.04 per animal more than  
dosing at the exact, correct dose. Dosing all animals at the lot average weight plus 50 lb costs 
$6.24 per animal more; dosing all animals at lot average minus 50 lb costs $4.01 per animal 
more.  These differences can be seen graphically at the 50th percentile on Figure 3.3 for the entire 
group of animals; the per animal values in Table 3.5 were determined by dividing the total lot 
costs by the respective number of animals.  It is observed, in certain instances, that dosing at a 50 
lb increment below the lot average weight can be cost beneficial.  The cost savings come from the 
high cost per mL of Draxxin®.  In lots E and F, the skewness aids in under dosing being the more 
cost efficient protocol.  The heightened concentration of animals around the mean in the under-
weight class is far outweighed by the large tail of animal weight distributions in the overweight 
class. 
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Table 3.5. Differences in cost from exact weight based dosing on (a) lot average weight, (b) lot average weight 
plus 50 lb, and (c) lot average weight minus 50 lb for Draxxin® on a per lot basis and a per head basis. 
   
 
Cost ($) per lot Cost ($) per animal 
Lot # 
Lot weight 
Ave, SD n Exact 
(a) 
Ave 
(b) 
Ave+50 
(c) 
Ave(50) Exact 
(a) 
Ave 
(b) 
Ave+50 
(c) 
Ave(50) 
A 1007, 105 75 -- 187.39   350.26  
         
257.37  --  2.50   4.67   3.43  
B 639, 69 81 -- 322.25 463.74  
           
66.23  --  3.98   5.73   0.82  
C 662, 76 126 -- 718.61   960.42  
         
642.25  --  5.70   7.62   5.10  
D 631, 41 35 --   13.81   141.68  
           
55.50  --  0.18   1.89   0.74  
E 329, 58 30 --  113.71   51.00  
           
70.35  --  3.79   1.70   2.35  
F 931, 113 47 --    39.76   178.47  
         
(29.12) --  0.85   3.80   (0.62) 
G 585, 77 68 --  211.73   263.24  
          
188.02  --  3.11   3.87   2.77  
H 470, 104 70 --  252.82  358.87  
  
(10.87) --  3.61  5.13  (0.16) 
I 1,129,113 54 --  122.35  276.11  
        
236.25  --  2.27   5.11   4.38  
J 476, 88 69 --  133.68  313.80  
         
139.57  --  1.94   4.55   2.02  
All 693, 242 652 -- 
     
3,938.81  
      
4,067.15  
      
2,613.77  --  6.04   6.24   4.01  
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Implications 
Producers many times assume that use of the average weight for a group of animals is 
good enough for administering weight-based medications.  However, whether or not it really is 
good enough depends upon how much variability exists in the group, and the associated risks 
from large deviations from the average.  Table 3.1 shows that even within small groups of cattle, 
substantial variation in weight exists, and use of exact weight is cost effective when administering 
weight-based products compared to other dosing schemes.  Under dosage of cattle limits the 
product effectiveness and increases the costs associated with morbidity.   
The differences in economic efficiency are directly related to the cost of the product, and 
the associated differences in effectiveness as well as the weight distribution.  Use of the product 
Draxxin® (a popular and expensive antimicrobial used in the U.S. cattle industry) at an exact, 
weight-based dose produced a cost savings of $6.04 per animal was predicted as compared to 
simply using the average lot weight for each animal’s dose.  Procedures employed here will work 
for any weight-based medication where the input parameters are known.   
The nature of this economic model is dynamic in that the input parameters can be altered to 
reflect any individual’s respective production setting, new antibiotic or optimal protocol given 
certain levels of variation.  Given known weights and distributions, and the parameters of the 
drug in question, this method could be used to determine at what point a given dosing protocol 
becomes interchangeable with respect to lot weights, standard deviations, or distributions.  
By reducing the associated costs of production, beef producers can potentially make their 
products more accessible to consumers. The own price elasticity of beef was said to be -.621, so 
any cost reductions observed can help to keep beef price relevant as compared to substitutes at 
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the retail level (USDA, 2008).  Producers can often get caught up in the added value of the 
marketing scheme while losing sight of the costs of production.  As with most commodity 
products, the beef industry is at the mercy of consumer demand.  Production costs need to be 
weighed just as heavily as added or retained value in production. 
In order for producers to evaluate and decrease costs of production, all potential impacts 
that stem from the use of weight-based products must be considered, not just simply cost of 
product and use of average weights of lots.  The use of individual animal weights to determine 
per head dosing of Draxxin® is more cost effective than using lot averages when there is typical 
weight variation, but especially when there is heightened variation.  This concept would appear to 
extend to all weight-based pharmaceutical products in general.     
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CHAPTER IV 
CONCLUSIONS 
 
 The amount of variation within groups of cattle is the main limiting factor  determining 
whether average dosing or deviations from the average is an appropriate dosing regimen.  Off 
label dosing potentially places limitations on the drugs’ efficacy, leading to additional costs 
associated with increased morbidity or heightens product waste and drives up production costs.  
The use of individual animal weights to determine per head dosing of Draxxin® is more cost 
effective than using lot averages when there is typical weight variation, but especially when there 
is heightened variation.   This concept would appear to be valid with the use of any weight-based 
pharmaceutical product.   
Using the least amount of any pharmaceutical in the most efficient manner in an effort to 
keep cattle healthy, while minimizing costs, is the ultimate goal in any production setting.  By 
reducing the associated costs of production, beef producers can potentially make their products 
more accessible to consumers.  Increased awareness of the additional benefits of precision dosing 
in weight- based medications is crucial to avoiding mandated action against producers.  
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